Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 for Prevention of Restenosis in SFA
NCT00518284Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2008
- Primary completion
- Aug 2009
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in peripheral artery disease (PAD), sponsored by Celgene Corporation. Started Jan 2008; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT00518284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00518284.